AlzChem Group Balance Sheet Health
Financial Health criteria checks 6/6
AlzChem Group has a total shareholder equity of €163.6M and total debt of €57.5M, which brings its debt-to-equity ratio to 35.2%. Its total assets and total liabilities are €424.7M and €261.1M respectively. AlzChem Group's EBIT is €53.8M making its interest coverage ratio 13.4. It has cash and short-term investments of €11.9M.
Key information
35.2%
Debt to equity ratio
€57.50m
Debt
Interest coverage ratio | 13.4x |
Cash | €11.88m |
Equity | €163.56m |
Total liabilities | €261.12m |
Total assets | €424.68m |
Recent financial health updates
No updates
Recent updates
The Market Lifts AlzChem Group AG (ETR:ACT) Shares 26% But It Can Do More
Mar 07Why AlzChem Group AG (ETR:ACT) Could Be Worth Watching
Nov 01Is There An Opportunity With AlzChem Group AG's (ETR:ACT) 42% Undervaluation?
Oct 12AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
May 06AlzChem Group AG's (ETR:ACT) CEO Compensation Is Looking A Bit Stretched At The Moment
May 05AlzChem Group (ETR:ACT) Will Pay A Larger Dividend Than Last Year At €1.05
Apr 05AlzChem Group (ETR:ACT) Is Increasing Its Dividend To €1.05
Mar 04AlzChem Group (ETR:ACT) Is Paying Out A Larger Dividend Than Last Year
Apr 24AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.00
Mar 29AlzChem Group (ETR:ACT) Has Announced That It Will Be Increasing Its Dividend To €1.00
Feb 27AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Nov 23Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?
Jun 10At €24.50, Is AlzChem Group AG (ETR:ACT) Worth Looking At Closely?
Apr 07AlzChem Group AG (ETR:ACT) Is Yielding 3.0% - But Is It A Buy?
Mar 23AlzChem Group AG's (ETR:ACT) Intrinsic Value Is Potentially 32% Above Its Share Price
Mar 10Is AlzChem Group AG's (ETR:ACT) Recent Stock Performance Influenced By Its Fundamentals In Any Way?
Feb 24Our Take On The Returns On Capital At AlzChem Group (ETR:ACT)
Feb 11Update: AlzChem Group (ETR:ACT) Stock Gained 13% In The Last Year
Aug 07Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
Jul 20Does This Valuation Of AlzChem Group AG (ETR:ACT) Imply Investors Are Overpaying?
Jul 03Financial Position Analysis
Short Term Liabilities: ACT's short term assets (€216.6M) exceed its short term liabilities (€82.6M).
Long Term Liabilities: ACT's short term assets (€216.6M) exceed its long term liabilities (€178.5M).
Debt to Equity History and Analysis
Debt Level: ACT's net debt to equity ratio (27.9%) is considered satisfactory.
Reducing Debt: ACT's debt to equity ratio has reduced from 84.7% to 35.2% over the past 5 years.
Debt Coverage: ACT's debt is well covered by operating cash flow (126.4%).
Interest Coverage: ACT's interest payments on its debt are well covered by EBIT (13.4x coverage).